Hepatitis A Virus
6
0
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Inactivated Hepatitis A Vaccine Ihav
Research Leaders
5 sponsors active, led by Merck Sharp & Dohme LLC
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
67%
4 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (6)
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Immunity With Acute Hepatits A
Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)
Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)
Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents
Research Network
Common Treatments
- Inactivated Hepatitis A Vaccine Ihav1
- Comparator Infanrix1
- Comparator Prevnar Pneumococcal 7valent Conjugate Vaccine1
- Comparator Proquad Measles Mumps Rubella And Varicella Vaccine1
- Comparator Vaqta1
Active Sponsors
- Merck Sharp & Dohme LLC2
- Faculty of Medicine, Chiang Mai University2
- Chiang Mai University2
- Assiut University1
- Sanofi Pasteur, a Sanofi Company1
Top Investigators
Department of Pediatrics, Faculty of Medicine, Chiang Mai University
Department of Pediatrics, Faculty of Medicine, Chiang Mai University
Related Conditions
- Hepatitis A4
- Vaccinepreventable Diseases2